W
William J. Tremaine
Researcher at Mayo Clinic
Publications - 290
Citations - 26053
William J. Tremaine is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Ulcerative colitis & Inflammatory bowel disease. The author has an hindex of 80, co-authored 282 publications receiving 24233 citations. Previous affiliations of William J. Tremaine include University of Paris & Cedars-Sinai Medical Center.
Papers
More filters
Journal ArticleDOI
Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis.
Christophe Penna,Roger R. Dozois,William J. Tremaine,William J. Sandborn,Nicholas F. LaRusso,Cathy D. Schleck,Duane M. Ilstrup +6 more
TL;DR: The strong correlation between PSC and pouchitis suggest a common link in their pathogenesis and may be associated with pouchitis after ileal pouch-anal anastomosis.
Journal ArticleDOI
Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.
Edward V. Loftus,Marc D. Silverstein,William J. Sandborn,William J. Tremaine,William S. Harmsen,Alan R. Zinsmeister +5 more
TL;DR: The overall incidence rate of ulcerative colitis in Olmsted County increased until the 1970s, and remained stable thereafter, and was similar to that of the general population.
Journal ArticleDOI
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota.
Tine Jess,Edward V. Loftus,Fernando Velayos,W. Scott Harmsen,Alan R. Zinsmeister,Thomas C. Smyrk,Cathy D. Schleck,William J. Tremaine,L. Joseph Melton,Pia Munkholm,William J. Sandborn +10 more
TL;DR: The risk for colorectal cancer was not increased among ulcerative colitis patients overall, but appeared to be increased among those with extensive colitis, including Crohn's disease patients, who also had a 40-fold excess risk for small-bowel cancer.
Journal ArticleDOI
American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
TL;DR: This work was funded in part by the National Institutes of Health and the generosity of the generous donors of the University of Pennsylvania and the City of Philadelphia.
Journal ArticleDOI
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
Bruce E. Sands,William J. Tremaine,William J. Sandborn,Paul Rutgeerts,Stephen B. Hanauer,Lloyd Mayer,Stephan R. Targan,Daniel K. Podolsky +7 more
TL;DR: Infliximab was well tolerated and may provide clinical benefit for some patients with steroid-refractory ulcerative colitis and may be well tolerated in relation to corticosteroid dosage.